VIR-5500 Shows Remarkable Prostate Cancer Results

Early-stage trials of VIR-5500, a new immunotherapy drug for advanced prostate cancer, have shown 'remarkable' results. The drug, developed with funding from Vir Biotechnology and led by Professor Johann de Bono at the Institute of Cancer Research and the Royal Marsden Hospital, demonstrated its ability to shrink tumors or halt their growth in almost half of the patients, with 88% experiencing only mild side effects. VIR-5500 utilizes a 'cloaking device' to activate only at the tumor site, minimizing adverse reactions. These findings, presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium, offer significant hope for patients who have stopped responding to other treatments, potentially leading to a new class of effective therapies for prostate cancer.